Relugolix

Relugolix is a pharmaceutical-grade active ingredient classified as Antineoplastic / CYP17 Inhibitor. Mediocon Inc supplies high-purity Relugolix API conforming to IP / BP / EP / USP specifications, manufactured in our GMP-certified facility in Aurangabad, Maharashtra, India.

Relugolix works by cyp17 inhibitor mechanism to provide therapeutic efficacy. It is used as a critical raw material in finished dosage form manufacturing for global pharmaceutical markets.

Key Features

• High-purity pharmaceutical grade API
• IP/BP/EP/USP compliant
• Full CoA and MSDS documentation
• GMP certified manufacturing

Applications

• Metastatic castration-resistant prostate cancer
• Hormone-sensitive prostate cancer
• Combination therapy with prednisone
• Oncology research

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings